Altre lingue Lexaria Bioscience Corp.

Azioni

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 03/05/2024			Variaz. 5gg	Var. 1 gen.
3,13 ^USD	+4,33%		+33,19%	+150,40%

16/04	Lexaria Bioscience Corp. riceve l'approvazione del comitato etico per iniziare un nuovo studio sul GLP-1	CI
09/04	Lexaria Bioscience Corp. Riporta i risultati degli utili per il secondo trimestre e i sei mesi conclusi il 29 febbraio 2024	CI

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance	30/04
Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	16/04
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	16/04
Lexaria Bioscience : Corporate Highlight Sheet	11/04
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	09/04
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents	02/04
Lexaria Awarded New Patents	02/04
Lexaria Bioscience : Amendment of a Material Definitive Agreement - Form 8-K	21/03
Lexaria to Present at The LD Micro Invitational XIV	21/03
Lexaria Bioscience Names Nelson Cabatuan as Finance Chief	14/03
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	14/03
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	14/03
Lexaria Bioscience : Corporate Highlight Sheet	08/03
Lexaria Awards Contract For Next GLP-1 Human Pilot Study	07/03
Sector Update: Health Care Stocks Retreating Late Afternoon	05/03
Sector Update: Health Care	05/03
Lexaria Bioscience to Start Diabetes, Weight Loss Animal Study; Shares Rise	05/03
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1	05/03
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1	05/03
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1	04/03

Non ci sono risultati per questa ricerca